Form 4: HealthEquity Director Evelyn S. Dilsaver Executes Stock Options and Sells Shares

Evelyn S. Dilsaver, a director at HealthEquity, Inc., exercised stock options and sold shares of common stock on March 26, 2024.

Summary

• On March 26, 2024, Evelyn S. Dilsaver, a director of HealthEquity, Inc., engaged in transactions involving the company's stock.
• Dilsaver exercised stock options to acquire 32,500 shares of common stock at an exercise price of $14 per share.
• Simultaneously, Dilsaver sold 32,500 shares of common stock at a weighted average price of $79.2876, with individual sales ranging from $78.86 to $79.73.
• Following these transactions, Dilsaver directly owns 32,123 shares of HealthEquity common stock.
• Dilsaver also holds options to purchase an additional 23,351 shares at prices of $21.27, $50.41 and $66.06.
• The power of attorney given by Ms. Dilsaver was previously filed with the U.S. Securities and Exchange Commission on June 26, 2023.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly listed companies like HealthEquity.
• Comparing Dilsaver's transactions to those of other directors in similar healthcare technology companies would provide a better understanding of whether this activity is typical or unusual.
• Companies like Teladoc Health, GoodRx, and Accolade could be considered peers for comparison purposes.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as insider sales can sometimes be interpreted as a lack of confidence in the company, although this is a routine transaction.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates